Elite Pharma gets FDA OK for generic Requip XL (ELTP)

Elite Pharmaceuticals (ELTP) announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP).

Rhea-AI Filing Summary

Elite Pharmaceuticals (ELTP) announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP). The approval covers 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths used to treat symptoms of Parkinson’s disease. The product will be marketed and sold under the Elite Laboratories, Inc. label.

The company furnished a press release with these details as Exhibit 99.1. Information in this item and the press release is provided under Regulation FD and is not deemed filed under the Exchange Act.

Positive

• FDA approval for a generic Ropinirole ER (Requip XL) across 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths, adding an approved product to the portfolio.

Negative

• None.

Insights

Pharma regulatory and generics analyst

FDA approval adds a new generic product line for ELTP.

Elite Pharmaceuticals received FDA approval for generic Requip XL (Ropinirole ER) across five tablet strengths. Ropinirole is a non‑ergoline dopamine agonist indicated for Parkinson’s disease symptoms. This expands Elite’s approved product portfolio under the Elite Laboratories, Inc. label.

As a generic approval, commercial outcomes depend on launch timing, channel access, and competitive pricing versus existing generics. The disclosure does not specify revenue potential, market size, or exclusivity, so financial impact cannot be inferred from this excerpt.

The press release was furnished on November 12, 2025 as Exhibit 99.1. Subsequent disclosures may detail shipment timing, initial orders, and distribution partners, which would clarify commercial traction.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Elite Pharmaceuticals (ELTP) announce?

Elite reported FDA approval for a generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths.

Which indications does Ropinirole address?

Ropinirole is a non-ergoline dopamine agonist used to treat symptoms of Parkinson’s disease.

Under what label will the product be sold?

The approved product will be marketed and sold under the Elite Laboratories, Inc. label.

Where can I find the official company communication?

Details are in the company’s press release furnished as Exhibit 99.1.

Is the information deemed filed under the Exchange Act?

No. The information furnished under Item 7.01 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 07:15 AM Learn about SEC filing dates

false 0001053369 0001053369 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

November 12, 2025

Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS INC /NV/

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-15697		22-3542636
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

(201) 750-2646

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ELTP		OTCQB

Item 7.01. Regulation FD Disclosure

On November 12, 2025, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it received approval from the US Food and Drug Administration (FDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat symptoms of Parkinson’s disease. This product will be marketed and sold under the Elite Laboratories, Inc. label.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2025	ELITE PHARMACEUTICALS, INC.
	By:	/s/ Nasrat Hakim
		Nasrat Hakim, President and CEO